Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: A global developer, manufacturer, and marketer of specialized scientific instruments used to accelerate drug discovery research. The company serves pharmaceutical and biotechnology companies, universities, and government laboratories in over 100 countries. Its strategy relies on a broad portfolio of over 20,000 products in niche markets (ADMET screening, molecular biology, genomics, proteomics, and high-throughput screening) to reduce dependency on single technologies and avoid direct competition with major instrument companies.
Key Financial Metrics
| Metric | 2003 | 2002 | Change |
|---|---|---|---|
| Total Revenues | $87.1 million | $57.4 million | +52% |
| Net Income | $4.3 million | $0.7 million | +476% |
| Operating Income | $7.7 million | $1.6 million | +369% |
| Gross Margin | 50.2% | 50.2% | 0% |
| Operating Cash Flow | $2.0 million | $0.8 million | +151% |
| Cash and Equivalents | $8.2 million | $15.3 million | -$7.1 million |
| Long-Term Debt | $12.8 million | $0.4 million | Significant Increase |
| Working Capital | $40.2 million | $31.8 million | +$8.4 million |
Notes: Revenue growth was primarily driven by acquisitions in 2002 and 2003 (Genomic Solutions, GeneMachines, BioRobotics, Hoefer, BTX). Approximately 40% of 2003 revenue was derived from capital equipment products. International sales represented approximately 50% of total revenue.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by $29.8 million (52%) compared to 2002. This was largely due to the full-year impact of 2002 acquisitions and new 2003 acquisitions. Foreign exchange effects (strengthening of the British pound and Euro) contributed favorably.
- Expense Increases: Sales and marketing expenses rose 82% to $15.4 million, and General and Administrative expenses rose 18% to $10.9 million, primarily due to the integration of acquired businesses.
- Debt Structure: The company entered a $20 million revolving credit facility with Brown Brothers Harriman in November 2003. As of year-end, $12.7 million was drawn, significantly increasing long-term debt compared to the prior year.
- Legal Settlements: The company incurred a $1.3 million settlement with Affymetrix and a $0.8 million settlement with former shareholders of Union Biometrica, impacting operating cash flow and net income.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: Management expects available cash, operating cash flow, and debt capacity to be sufficient to finance operations for at least 12 months. The company anticipates returning to solid organic growth alongside acquisition-driven growth but notes economic uncertainty. No specific numerical guidance for 2004 was provided in the text.
Unusual Items:
- Legal Costs: $1.3 million paid to Affymetrix (settled June 2003) and $0.8 million paid to former Union Biometrica shareholders (settled August 2003).
- Acquisition Activity: Significant cash outflows ($22.4 million) for acquisitions including BTX, GeneMachines, BioRobotics, and Hoefer.
Risks and Contingencies:
- Capital Raising: The company may be unable to access public equity markets due to an outstanding amendment to a Form 8-K filing related to a previous acquisition. This limits financing options to private equity or additional borrowing.
- Customer Concentration: Amersham Biosciences accounted for 13% of 2003 revenues. The company relies on distribution agreements with Amersham for Biochrom and Hoefer products.
- Integration Risk: Risks associated with integrating recent acquisitions (Genomic Solutions, BTX, GeneMachines, BioRobotics, Hoefer) and realizing anticipated benefits.
- Seasonality: Quarterly revenues are subject to significant fluctuation due to the seasonal nature of capital equipment purchases and European purchasing patterns.
Investor Verification Checklist
- Form 8-K Status: Verify the status of the outstanding Form 8-K amendment mentioned in the liquidity section, as it currently restricts access to public equity markets.
- Acquisition Integration: Monitor the integration progress and revenue contribution of recent acquisitions (GeneMachines, BioRobotics, Hoefer) to ensure they meet projected growth targets.
- Debt Covenants: Review compliance with the financial covenants of the $20 million Brown Brothers Harriman credit facility (income, debt coverage, cash flow, working capital).
- Amersham Relationship: Assess the stability of the distribution agreement with Amersham Biosciences, particularly in light of General Electric's acquisition of Amersham plc.
- Legal Appeals: Track the status of the pending appeal by Paul D. Grindle regarding the 1996 Harvard Apparatus acquisition, despite the company's victory in the lower court.